🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "significant breakthrough" in the fight against increasingly resistant strains of the pathogen, according to scientists.

An International Health Concern

Gonorrhoea infections are escalating worldwide, with data suggesting in excess of 82 million new cases each year. Particularly high rates are reported in the African continent and countries within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. In England, cases have hit a record high, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune advancement in the context of growing infection rates, escalating drug resistance and the extremely scarce treatment choices presently on offer.”

Medical experts are increasingly worried about the increase in drug-resistant strains. The global health body has classified it as a "critical concern". A tracking program revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Treatment Options Secure Authorization

One new antibiotic, alternatively called Nuzolvence, was approved by the US Food and Drug Administration in mid-December for use against gonorrhoea. This disease can lead to significant complications, including infertility. Experts believe that specific application of this new drug will help delay the development of resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This drug, which is additionally indicated for urinary tract infections, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment stemmed from a innovative non-profit model for antibiotic development. The non-profit organisation GARDP worked alongside the drug firm Innoviva to bring it to fruition.

“This approval represents a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which previously has been outpacing medical innovation.”

Clinical Trial Outcomes and Worldwide Availability

As per findings published in a major medical journal, zoliflodacin cured more than 90% of uncomplicated infections. This puts it on an similar efficacy with the existing first-line therapy, which involves an injection and a pill. The research enrolled over 900 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the rights to register and commercialise the drug in many low-income and middle-income countries.

Clinicians on the front lines have expressed hope. Access to a single-dose, oral treatment such as this is seen as a "critical tool" for gonorrhoea control. This is viewed as vital to alleviate the strain of the illness for people and to stop the proliferation of extremely resistant gonorrhoea globally.